Loading
Cancer, Hypoxia, and Metabolism / Endometrial and Cervical Cancer Treatments / Angiogenesis and VEGF in Cancer · Review
Frontiers in Oncology · September 10, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review that synthesizes mechanistic evidence linking hypoxia-inducible factor 1-alpha (HIF-1α) to cervical cancer aggression through angiogenesis, EMT, immune modulation, and therapy resistance. The authors identify HIF-1α pathway inhibition and hypoxia signatures as promising future therapeutic targets but explicitly state that specific clinical trials are still needed to validate impact on survival and safety.
Narrative review. Patients with cervical intraepithelial neoplasia and cervical cancer (literature review, no enrolled cohort).
HIF-1α is a key inducer of aggressive phenotypes in cervical cancer, promoting angiogenesis, invasion, epithelial-mesenchymal transition, immune microenvironment modulation, and radiotherapy/chemotherapy resistance HIF-1α is involved in expression of genes related to angiogenesis, apoptosis and progression including GLUT1, uPAR, BIRC5, EPO, EpoR, LIMD1, VHL, MET and pro-angiogenic genes (VEGF, PGF, PDGF-β, PAI-1, MMP-2, MMP-9, ANG-1, ANG-2) Balance between antitumor factors (miR-143) and protumor factors can define progression of cervical neoplasia
No clinical trial data, survival outcomes, or safety data reported; review is mechanistic and preclinical in nature HIF-1α pathway inhibitors and hypoxia signatures are identified as promising tools for optimizing treatment outcomes, though specific clinical trials remain needed to validate impact on survival and safety
Clinicians should recognize HIF-1α as a mechanistic driver of cervical cancer aggression, but direct clinical application awaits validation through prospective trials. Current evidence does not yet support routine clinical use of HIF-1α inhibitors or hypoxia profiling for patient management.
A narrative review synthesizing mechanistic evidence and experimental findings on HIF-1α in cervical cancer progression, raising questions about therapeutic targets rather than reporting clinical trial outcomes or definitive clinical evidence.
As stated by the source record.
Clinicians should recognize HIF-1α as a mechanistic driver of cervical cancer aggression, but direct clinical application awaits validation through prospective trials. Current evidence does not yet support routine clinical use of HIF-1α inhibitors or hypoxia profiling for patient management.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Cervical cancer represents a global public health problem, hence the importance of optimizing therapeutic options and expanding knowledge of prognostic markers. Clinical and experimental evidence shows that hypoxia-inducible factor (HIF) is a key inducer of aggressive phenotypes in cervical cancer: promoting angiogenesis, invasion, epithelial-mesenchymal transition (EMT), modulation of the immune microenvironment, and contributing to resistance to radiotherapy/chemotherapy in a possible synergistic effect with the human papilloma virus oncogenes. Hypoxic microenvironments that modulate the early activation of HIF pathways may be present in pre-invasive lesions and favor the acquisition of invasive phenotypes that precede invasion. This review highlights the mechanisms of HIF-1α in the progression of cervical intraepithelial neoplasia and cervical cancer. In this regard, HIF-1α is involved in the expression of genes related to angiogenesis, apoptosis and progression such as GLUT1, uPAR, BIRC5, EPO, EpoR, LIMD1, VHL, MET and pro-angiogenic genes (VEGF, PGF, PDGF-β, PAI-1, MMP-2, MMP-9, ANG-1, ANG-2, using pathways such as YAP/TA2. However, the balance between antitumor factors (miR-143) and protumor factors can define the progression of this neoplasia. In the future, the characterization of hypoxia signatures and the evaluation of HIF-1α pathway inhibitors are promising tools for optimizing outcomes in the treatment of cervical cancer, integrated with modern, high-precision radiation therapy techniques and predictive models based on imaging and artificial intelligence, which represent a key pillar of personalized oncology in cervical cancer, with the potential to improve tumor control and reduce toxicity; however, specific clinical trials are still needed to validate their impact on survival and safety.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.